WO2017140913A3 - Fusion proteins - Google Patents

Fusion proteins Download PDF

Info

Publication number
WO2017140913A3
WO2017140913A3 PCT/EP2017/053816 EP2017053816W WO2017140913A3 WO 2017140913 A3 WO2017140913 A3 WO 2017140913A3 EP 2017053816 W EP2017053816 W EP 2017053816W WO 2017140913 A3 WO2017140913 A3 WO 2017140913A3
Authority
WO
WIPO (PCT)
Prior art keywords
der
fusion proteins
fusion protein
cysteine residues
fusion
Prior art date
Application number
PCT/EP2017/053816
Other languages
French (fr)
Other versions
WO2017140913A2 (en
Inventor
Juan Andrés ASTURIAS ORTEGA
Mikel SANTOS ETXEPARE
Maria del Carmen ARILLA RODRIGUEZ
Original Assignee
Roxall Medicina España, S.A.U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roxall Medicina España, S.A.U filed Critical Roxall Medicina España, S.A.U
Publication of WO2017140913A2 publication Critical patent/WO2017140913A2/en
Publication of WO2017140913A3 publication Critical patent/WO2017140913A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides fusion proteins derived from allergens of Dermatophagoides pteronyssinus. In particular, the invention provides a fusion protein sharing at least 97% identity with SEQ ID NO:1. Such a fusion protein may comprise no more than 5 cysteine residues. Suitably the fusion protein does not comprise any cysteine residues. The invention also provides a fusion protein comprising fragments of amino acid sequences from Der p 1 and Der p 2, wherein cysteine residues present in the fragments of Der p 1 and Der p 2 from which the fusion protein is derived have been substituted such that the Der p 1 and Der p 2 fragments contain no cysteine residues. Also disclosed are medical uses of such fusion proteins, methods of treatment using such fusion proteins, and pharmaceutical compositions comprising such proteins, all of which are useful in the context of prevention or treatment of house dust mite allergies. Furthermore, the invention relates to nucleic acids encoding fusion proteins derived from allergens of Dermatophagoides pteronyssinus, and methods of purifying, producing and of manufacturing such fusion proteins.
PCT/EP2017/053816 2016-02-18 2017-02-20 Fusion proteins WO2017140913A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602850.8A GB201602850D0 (en) 2016-02-18 2016-02-18 Fusion proteins
GB1602850.8 2016-02-18

Publications (2)

Publication Number Publication Date
WO2017140913A2 WO2017140913A2 (en) 2017-08-24
WO2017140913A3 true WO2017140913A3 (en) 2017-09-28

Family

ID=55752848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/053816 WO2017140913A2 (en) 2016-02-18 2017-02-20 Fusion proteins

Country Status (2)

Country Link
GB (1) GB201602850D0 (en)
WO (1) WO2017140913A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
CN117362453B (en) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 Derf1 recombinant antigen, preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103067A1 (en) * 2004-04-23 2005-11-03 Novexin Limited Methods and kits for stabilising, protecting and solubilising proteins
WO2007031080A1 (en) * 2005-09-15 2007-03-22 Alk-Abelló A/S A method for quantification of allergens
WO2008000783A1 (en) * 2006-06-29 2008-01-03 Biotech Tools S.A. A method for the production of hydrolyzed allergen
WO2009118642A2 (en) * 2008-03-25 2009-10-01 Bial Industrial Farmaceutica S.A. Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
WO2012072678A1 (en) * 2010-12-01 2012-06-07 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103067A1 (en) * 2004-04-23 2005-11-03 Novexin Limited Methods and kits for stabilising, protecting and solubilising proteins
WO2007031080A1 (en) * 2005-09-15 2007-03-22 Alk-Abelló A/S A method for quantification of allergens
WO2008000783A1 (en) * 2006-06-29 2008-01-03 Biotech Tools S.A. A method for the production of hydrolyzed allergen
WO2009118642A2 (en) * 2008-03-25 2009-10-01 Bial Industrial Farmaceutica S.A. Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
WO2012072678A1 (en) * 2010-12-01 2012-06-07 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy

Also Published As

Publication number Publication date
WO2017140913A2 (en) 2017-08-24
GB201602850D0 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2014118360A3 (en) Carbohydrate degrading polypeptide and uses thereof
WO2016118014A3 (en) Anti-senescence compounds and uses thereof
MX2019015502A (en) Modified l-asparaginase.
MX2019006349A (en) Novel recombinant prefusion rsv f proteins and uses thereof.
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
EA201890220A1 (en) VACCINE AGAINST RSV
MY188897A (en) Factor viii compositions and methods of making and using same
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2014202622A3 (en) Rasamsonia gene and use thereof
MX2023001877A (en) Engineered meganucleases specific for recognition sequences in the pcsk9 gene.
WO2011036443A3 (en) Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
MX2015003310A (en) Novel il-17a binding molecules and medical uses thereof.
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
BR112017014609A2 (en) Disease-related protein coding gene and their use in the regulation of plant disease resistance
WO2018215525A8 (en) Mic-1 compounds and uses thereof
WO2018013775A3 (en) Granulin compositions and uses related thereto
MX2017016227A (en) Broad-spectrum anti-infective peptides.
WO2017060318A3 (en) Kaurenoic acid hydroxylases
WO2015086686A3 (en) Protease resistant peptides
WO2017140913A3 (en) Fusion proteins
MY187334A (en) Xylanase
WO2017211922A3 (en) Protease-resistant mono-lipidated peptides
EA201692439A1 (en) PROLIN-SPECIFIC ENDOPROTEASIS AND ITS APPLICATION
WO2015043566A8 (en) Cyclic amyloid-beta-binding peptides and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17705908

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17705908

Country of ref document: EP

Kind code of ref document: A2